Abstract:Background Gut microbiota and its metabolites are important factors affecting the treatment and progression of ulcerative colitis, but the mechanism was still unclear. This study aims to study the efficacy of Clostridium butyricum MIYAIRI 588 (CBM) on colitis mice and explore the effect on IgA-coated microbiota of CBM and metabolite butyrate. Methods Twenty-four Balb/c mice with specific pathogen-free were randomly divided into four groups of six mice each. The Control group were fed normal drinking water, and the other three groups were drinking water which contained 3% DSS for seven days. In this study, CBM (106CFU/mL) and its main metabolite butyrate (0.2mg/kg) were used to intervene in the colitis mouse by oral gavage. The changes in weight loss, colon length and histopathology of colitis mice were observed and recorded. RNA-sequencing was used to detect the transcriptional changes in the colon in mice, and the percentage of IgA-coated microbiota in feces was detected by flow cytometry. Results From the fourth day after the intervention of CBM and butyrate, the weight loss and colon shorten of colitis mice had been alleviated (IDDF2022-ABS-0275 Figure 1A. Weight loss of mice after CBM and butyrate treatment) (IDDF2022-ABS-0275 Figure 1B. Colon length of mice). Besides, CBM and metabolite butyrate can relieve the colonic pathology, which is reflected in reducing the damage of the mucosa structure and the infiltration of inflammatory cells (IDDF2022-ABS-0275 Figure 1C. Histopathological analysis of colon sections which stained by hematoxylin-eosin staining). RNA-sequencing showed that by KEGG enrichment analysis of differentially expressed genes, numerous signaling pathways concerning immunity and metabolism could be observed, including the pathway of the intestinal immune network for IgA production (IDDF2022-ABS-0275 Figure 1D. KEGG enrichment analysis of butyrate treatment on colitis mice). Furthermore, results showed that the proportion of IgA-coated microbiota in cecal contents of mice with colitis increased significantly. However, both CBM and metabolite butyrate could significantly reduce the proportion of IgA-coated microbiota (IDDF2022-ABS-0275 Figure 1E. The proportion of IgA-coated microbiota after CBM and butyrate treatment) (IDDF2022-ABS-0275 Figure 1F. The statistical analysis of the percentage of IgA-coated microbiota). Conclusions The present study confirmed that CBM and metabolite butyrate could effectively alleviate DSS-induced colitis, might through regulating mucosal immune homeostasis by affecting IgA-coated microbiota. In summary, our study explored the interaction between gut microbiota and host immunity, and it provides theoretical support for the better use of probiotics.

Butyrolactone-I from marine fungi alleviates intestinal barrier damage caused by DSS through regulating Lactobacillus johnsonii and its metabolites in the intestine of mice

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice

Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis

Donkey Milk Lysozyme Ameliorates Dextran Sulfate Sodium-Induced Colitis by Improving Intestinal Barrier Function and Gut Microbiota Composition

Sodium Butyrate Alleviates Mouse Colitis by Regulating Gut Microbiota Dysbiosis

Prevention and Alleviation of Dextran Sulfate Sodium Salt-Induced Inflammatory Bowel Disease in Mice With Bacillus subtilis-Fermented Milk via Inhibition of the Inflammatory Responses and Regulation of the Intestinal Flora

Clostridium Butyricum Alleviates Intestinal Low-Grade Inflammation In Tnbs-Induced Irritable Bowel Syndrome In Mice By Regulating Functional Status Of Lamina Propria Dendritic Cells

Lactobacillus gasseri ATCC33323 affects the intestinal mucosal barrier to ameliorate DSS-induced colitis through the NR1I3-mediated regulation of E-cadherin

Butyrate Glycerides Protect against Intestinal Inflammation and Barrier Dysfunction in Mice

<i>Lactobacillus</i><i> plantarum</i> ZJUIDS04 alleviates DSS-induced colitis via modulating gut microbiota

Prevention and Curation of DSS-induced IBD in Mice With Bacillus Subtilis Fermented Milk via Inhibition of the Inflammatory Responses and Regulation of the Intestinal Flora

Sodium butyrate alleviates intestinal injury and microbial flora disturbance induced by lipopolysaccharides in rats

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Lactobacillus Johnsonii Glj001 Prevents Dss-Induced Colitis in Mice by Inhibiting M1 Macrophage Polarization Via Gut Microbiota-Scfas Axis

<i>Bifidobacterium longum</i> subsp. <i>longum</i> K5 alleviates inflammatory response and prevents intestinal barrier injury induced by LPS <i>in vitro</i> based on comparative genomics

IDDF2022-ABS-0275 Clostridium Btyricum and Metabolite Butyrate Relieve DSS-induced Colitis in Mice by Regulating IGA-coated Microbiota

Lacticaseibacillus casei IB1 Alleviates DSS-Induced Inflammatory Bowel Disease by Regulating the Microbiota and Restoring the Intestinal Epithelial Barrier

Orally Administered Lactobacillus rhamnosus CY12 Alleviates DSS-Induced Colitis in Mice by Restoring the Intestinal Barrier and Inhibiting the TLR4-MyD88-NF-κB Pathway via Intestinal Microbiota Modulation

Pretreatment with Bifidobacterium longum BAA2573 ameliorates dextran sulfate sodium (DSS)-induced colitis by modulating gut microbiota

Lactobacillus rhamnosus KBL2290 Ameliorates Gut Inflammation in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis